vs
Ensysce Biosciences, Inc.（ENSC）与Roivant Sciences Ltd.（ROIV）财务数据对比。点击上方公司名可切换其他公司
Roivant Sciences Ltd.的季度营收约是Ensysce Biosciences, Inc.的1.1倍（$2.0M vs $1.9M），Ensysce Biosciences, Inc.净利率更高（-147.0% vs -13301.2%，领先13154.2%），Ensysce Biosciences, Inc.同比增速更快（44.4% vs -77.8%），过去两年Ensysce Biosciences, Inc.的营收复合增速更高（107.9% vs -73.7%）
Ensysce Biosciences是一家临床阶段生物技术公司，专注于开发疼痛管理和肿瘤适应症领域的创新前药疗法，其专有平台可降低阿片类药物滥用风险并提升治疗有效性，面向全球医疗医药市场，重点解决未被满足的临床需求。
Roivant Sciences Ltd.是一家美国跨国医疗健康企业，2014年由维韦克·拉马斯瓦米创立，现任CEO为马特·格林。公司专注于将技术应用于药物研发领域，同时孵化运营多家生命科学与健康科技子公司，总部位于纽约，在波士顿、巴塞尔两大生物科技产业集群也设有核心办公点。
ENSC vs ROIV — 直观对比
营收规模更大
ROIV
是对方的1.1倍
$1.9M
营收增速更快
ENSC
高出122.2%
-77.8%
净利率更高
ENSC
高出13154.2%
-13301.2%
两年增速更快
ENSC
近两年复合增速
-73.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.9M | $2.0M |
| 净利润 | $-2.8M | $-265.9M |
| 毛利率 | — | — |
| 营业利润率 | -147.8% | -16966.1% |
| 净利率 | -147.0% | -13301.2% |
| 营收同比 | 44.4% | -77.8% |
| 净利润同比 | 22.3% | -257.0% |
| 每股收益（稀释后） | $-0.51 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENSCROIV
| Q4 25 | $1.9M | $2.0M | ||
| Q3 25 | $493.1K | $1.6M | ||
| Q2 25 | $1.4M | $2.2M | ||
| Q1 25 | $1.3M | $-39.6M | ||
| Q4 24 | $1.3M | $9.0M | ||
| Q3 24 | $3.4M | $4.5M | ||
| Q2 24 | — | $8.0M | ||
| Q1 24 | — | $28.9M |
净利润ENSCROIV
| Q4 25 | $-2.8M | $-265.9M | ||
| Q3 25 | $-3.7M | $-113.5M | ||
| Q2 25 | $-1.7M | $-223.4M | ||
| Q1 25 | $-1.9M | $-206.5M | ||
| Q4 24 | $-3.6M | $169.4M | ||
| Q3 24 | $661.8K | $-230.2M | ||
| Q2 24 | — | $95.3M | ||
| Q1 24 | — | $-151.1M |
营业利润率ENSCROIV
| Q4 25 | -147.8% | -16966.1% | ||
| Q3 25 | -758.7% | -19492.9% | ||
| Q2 25 | -127.6% | -13130.0% | ||
| Q1 25 | -149.1% | 674.8% | ||
| Q4 24 | -274.3% | -3042.6% | ||
| Q3 24 | 18.9% | -7636.0% | ||
| Q2 24 | — | -1279.5% | ||
| Q1 24 | — | -919.5% |
净利率ENSCROIV
| Q4 25 | -147.0% | -13301.2% | ||
| Q3 25 | -756.3% | -7225.9% | ||
| Q2 25 | -126.4% | -10292.9% | ||
| Q1 25 | -147.4% | 521.8% | ||
| Q4 24 | -273.4% | 1878.3% | ||
| Q3 24 | 19.4% | -5143.8% | ||
| Q2 24 | — | 1192.7% | ||
| Q1 24 | — | -522.3% |
每股收益（稀释后）ENSCROIV
| Q4 25 | $-0.51 | $-0.38 | ||
| Q3 25 | $-1.29 | $-0.17 | ||
| Q2 25 | $-0.79 | $-0.33 | ||
| Q1 25 | $-1.39 | $-0.28 | ||
| Q4 24 | $-0.89 | $0.23 | ||
| Q3 24 | $1.00 | $-0.31 | ||
| Q2 24 | — | $0.12 | ||
| Q1 24 | — | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.3M | $4.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.2M | $4.3B |
| 总资产 | $7.5M | $5.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ENSCROIV
| Q4 25 | $4.3M | $4.5B | ||
| Q3 25 | $1.7M | $4.4B | ||
| Q2 25 | $2.2M | $4.5B | ||
| Q1 25 | $3.1M | $4.9B | ||
| Q4 24 | $3.5M | $5.1B | ||
| Q3 24 | $4.2M | $5.4B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $6.5B |
总债务ENSCROIV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $311.7M | ||
| Q1 24 | — | $430.6M |
股东权益ENSCROIV
| Q4 25 | $3.2M | $4.3B | ||
| Q3 25 | $1.2M | $4.4B | ||
| Q2 25 | $3.4M | $4.3B | ||
| Q1 25 | $3.0M | $4.7B | ||
| Q4 24 | $3.7M | $5.2B | ||
| Q3 24 | $6.9M | $5.2B | ||
| Q2 24 | — | $5.4B | ||
| Q1 24 | — | $6.0B |
总资产ENSCROIV
| Q4 25 | $7.5M | $5.2B | ||
| Q3 25 | $3.2M | $5.1B | ||
| Q2 25 | $5.6M | $5.0B | ||
| Q1 25 | $4.6M | $5.4B | ||
| Q4 24 | $5.6M | $5.8B | ||
| Q3 24 | $9.4M | $6.2B | ||
| Q2 24 | — | $6.5B | ||
| Q1 24 | — | $7.2B |
负债/权益比ENSCROIV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | 0.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.5M | $-196.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-201.4M |
| 自由现金流率自由现金流/营收 | — | -10076.0% |
| 资本支出强度资本支出/营收 | — | 246.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-776.7M |
8季度趋势，按日历期对齐
经营现金流ENSCROIV
| Q4 25 | $-1.5M | $-196.5M | ||
| Q3 25 | $-1.9M | $-185.7M | ||
| Q2 25 | $-2.7M | $-204.4M | ||
| Q1 25 | $-1.7M | $-172.6M | ||
| Q4 24 | $-764.1K | $-207.3M | ||
| Q3 24 | $-1.0M | $-266.8M | ||
| Q2 24 | — | $-192.8M | ||
| Q1 24 | — | $-108.5M |
自由现金流ENSCROIV
| Q4 25 | — | $-201.4M | ||
| Q3 25 | — | $-193.5M | ||
| Q2 25 | — | $-208.4M | ||
| Q1 25 | — | $-173.4M | ||
| Q4 24 | — | $-209.1M | ||
| Q3 24 | — | $-267.8M | ||
| Q2 24 | — | $-193.8M | ||
| Q1 24 | — | $-108.8M |
自由现金流率ENSCROIV
| Q4 25 | — | -10076.0% | ||
| Q3 25 | — | -12317.8% | ||
| Q2 25 | — | -9604.5% | ||
| Q1 25 | — | 438.1% | ||
| Q4 24 | — | -2318.5% | ||
| Q3 24 | — | -5984.4% | ||
| Q2 24 | — | -2425.5% | ||
| Q1 24 | — | -376.1% |
资本支出强度ENSCROIV
| Q4 25 | — | 246.9% | ||
| Q3 25 | — | 499.6% | ||
| Q2 25 | — | 185.9% | ||
| Q1 25 | — | -2.0% | ||
| Q4 24 | — | 20.3% | ||
| Q3 24 | — | 22.3% | ||
| Q2 24 | — | 12.1% | ||
| Q1 24 | — | 1.2% |
现金转化率ENSCROIV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -1.22× | ||
| Q3 24 | -1.54× | — | ||
| Q2 24 | — | -2.02× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
